Running hot in customers' hands: existing deployments are being used harder than they were sized for
The model's full reasoning — Q2 2021 call → NOWe need to determine if management describes that the company's product/service is being used more intensively by existing customers than originally expected, with observable current usage behavior. The transcript discusses Firdapse sales, new patient enrollments, discontinuations, etc. Key points: Q2 net Firdapse sales $33.6M, up 14% vs Q2 2020, 11% vs Q1 2021. New patient enrollments 111% higher vs same quarter last year. First half 2021 new patient enrollments 42% higher than first half 2020. Discontinuation rates low (<15%), and discontinuations 25% lower than first half 2020. This indicates existing patients are staying on therapy longer, and new patients are enrolling at higher rates. But is this "heavier usage within existing relationships"? The growth is driven by new patient enrollments, not necessarily existing patients using more per patient. The question asks about intensity of usage per existing customer. Here, the product is a prescription drug; usage is per patient. The company is adding new patients, not increasing dosage per patient. The discontinuation rate is low, meaning patients stay on therapy, but that's not necessarily "more intensive" usage. The transcript mentions "steady new patient enrollments" and "stable discontinuation rates." There's no mention of existing patients increasing their dose or using more than planned. The growth is from new patients, not from existing patients consuming more. So the answer is NO. The phenomenon described is winning new patients, not heavier usage within existing relationships. Also, the company notes COVID impacts, but that's about market dynamics. No indication of existing base running hot. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| APYX | Apyx Medical Corporation | Q4 2023 | 2024-03-21 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
TJX · Q2 2021 → YESThe question is about whether management describes that the company's product, service, capacity, or offering — already deployed with existing customers — is being used more intensively than originall...
WES · Q3 2018 → YESThe question is about whether management describes that the company's product, service, capacity, or offering — already deployed with existing customers — is being used more intensively than originall...
BCE · Q2 2017 → YESThe question is about whether management describes that the company's product, service, capacity, or offering — already deployed with existing customers — is being used more intensively than originall...